Fig. 4: C18:2 upregulates CPT gene expression through PPAR-α.

a Jurkat cells were cultured with various concentrations of the PPAR-α agonist bezafibrate in vitro for 24 h and CPT mRNA levels were measured by RT-qPCR. b Jurkat cells were treated with 200 µM C18:2 in the absence or presence of 1 µg/mL PPAR-α antagonist GW6471 in vitro for 24 h and CPT mRNA levels were measured by RT-qPCR. c Mouse splenic CD4+ T cells were isolated and treated with 100 µM C18:2 in the absence or presence of 0.25 µg/mL GW6471 in vitro for 24 h. CPT mRNA levels were measured by RT-qPCR. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001